VTRS — Viatris Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1792044 ·
Last close
$17.56
Market Cap
$20.45B
52W High
$18.07
52W Low
$14.67
ADV30
10,088,333
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,517,000,000 | 1,157,200,000 | -20,200,000 | 176,400,000 | 36,834,600,000 | 1,804,200,000 | 22,176,900,000 |
| Dec 2025 | 3,703,600,000 | 1,147,900,000 | -157,500,000 | -340,100,000 | 37,193,100,000 | 1,322,400,000 | 22,481,800,000 |
| Sep 2025 | 3,759,900,000 | 1,371,500,000 | 234,500,000 | -128,200,000 | 37,920,400,000 | 975,300,000 | 22,702,800,000 |
| Jun 2025 | 3,582,100,000 | 1,332,900,000 | 185,400,000 | -4,600,000 | 38,411,500,000 | 566,400,000 | 22,841,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,315,900,000
Investing CF
$-427,700,000
Financing CF
$-1,293,900,000
CapEx
$-465,100,000
Dividends Paid
$-561,200,000
Buybacks
$-500,500,000
EPS Diluted TTM
$-2.96
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-388,300,000
Inventory
$3,999,200,000
Receivables
$3,347,100,000
ST Investments
$190,600,000
EBIT TTM
$-3,193,700,000
Pretax Income TTM
$-3,665,000,000
Interest Exp TTM
$471,300,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$14,562,599,936
EBITDA
$4,125,199,872
Free Cash Flow
$2,238,337,536
Enterprise Value
$32,659,345,408
Total Cash
$2,400,199,936
Total Debt
$14,609,999,872
Shares Out
1,164,552,654
Trailing EPS
$-0.30
Book Value
$12.59
ROE
-2.0%
ROA
2.3%
Div Yield
2.73%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 14,299,900,000 | 253,500,000 | -3,514,900,000 | 37,193,100,000 | 22,481,800,000 | — | 2,315,900,000 |
| Dec 2024 | 14,739,300,000 | 710,300,000 | -634,200,000 | 41,500,900,000 | 22,865,400,000 | — | 2,302,900,000 |
| Dec 2023 | 15,426,900,000 | 1,563,400,000 | 54,700,000 | 47,685,500,000 | 27,218,100,000 | — | 2,900,000,000 |
| Dec 2022 | 16,262,700,000 | 1,655,700,000 | 2,078,600,000 | 50,022,200,000 | 28,949,900,000 | — | 2,999,000,000 |
TTM Snapshot
Revenues TTM
$16,307,900,000
NetIncome TTM
$1,092,200,000
OpCashFlow TTM
$0
Assets (Latest)
$41,500,900,000
Forward EPS
$2.63
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INSM | INSMED Inc | $21.37B | $98.60 | — |
| GNMSF | GENMAB A/S | $17.75B | $289.16 | — |
| GMAB | GENMAB A/S | $17.72B | $28.87 | — |
| ROIV | Roivant Sciences Ltd. | $24.50B | $33.91 | — |
| UTHR | UNITED THERAPEUTICS Corp | $25.78B | $517.71 | — |
News headlines (Yahoo Finance, 1h cache)
Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?
2026-07-30 14:00 · Yahoo
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
2026-07-29 10:59 · Yahoo
Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)
2026-07-29 01:41 · Yahoo
3 Healthcare Stocks We Keep Off Our Radar
2026-07-24 16:33 · Yahoo
Trump Proposes 200% Generic Drug Tariffs, Sandoz Shares Drop 4.2%
2026-07-22 19:56 · Yahoo
Viatris’ Quarterly Earnings Preview: What You Need to Know
2026-07-22 10:45 · Yahoo
3 Unpopular Stocks We’re Skeptical Of
2026-07-20 11:27 · Yahoo
Financial Stocks Rally To New Highs. JPMorgan Is One Of Them.
2026-07-17 19:49 · Yahoo
VTRS or DHR: Which Is the Better Value Stock Right Now?
2026-07-09 15:40 · Yahoo
Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
2026-07-09 14:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.